<p>金卢瑟资本管理公司在最近向证券交易委员会（SEC）提交的 13F 表格中披露，在第二季度将其在诺华制药（NYSE:NVS - 免费报告）股票中的持股比例提高了 27.4%。该机构投资者在本季度额外购买了 3,038 股后，持有该公司 14,106 股股票。根据其最近的 SEC 文件，金卢瑟资本管理公司在诺华的持股价值为 1,707,000 美元。</p>
<ul>
<li>诺华的月球计划癌症疗法可能成为未来的增长驱动力</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也对该公司的持股进行了调整。中西部信托公司在第二季度新购入了价值约 32,297,000 美元的诺华股票。Parkside 金融银行和信托在第二季度将其在诺华的持股增加了 3.7%。Parkside 金融银行和信托目前持有 4,623 股该公司的股票，价值 559,000 美元，此前在上个季度又购买了 166 股。Prospera 金融服务公司在第二季度将其在诺华的持股增加了 21.0%。Prospera 金融服务公司目前持有 26,483 股该公司的股票，价值 3,206,000 美元，此前在上个季度又购买了 4,598 股。AE 财富管理公司在第二季度将其在诺华的持股增加了 8.6%。AE 财富管理公司目前持有 7,289 股该公司的股票，价值 882,000 美元，此前在上个季度又购买了 580 股。最后，Legacy 投资解决方案公司在第二季度新购入了价值约 30,000 美元的诺华股票。机构投资者和对冲基金持有该公司 13.12% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<p>NVS 最近成为多份分析师报告的主题。Weiss 评级在 10 月 31 日的报告中重申了对诺华股票的 “买入（b-）” 评级。Cfra 研究在 10 月 29 日的报告中将诺华的评级上调至 “持有”。德意志银行在 8 月 21 日的报告中重申了对诺华股票的 “买入” 评级。摩根士丹利在 10 月 31 日的研究报告中将诺华股票的评级从 “持平” 上调至 “超配”。最后，杰富瑞金融集团在 10 月 27 日的研究报告中重申了对诺华股票的 “持有” 评级。一位投资分析师对该股票给予了强烈买入评级，三位给予了买入评级，七位给予了持有评级，三位给予了卖出评级。根据 MarketBeat.com 的数据，诺华目前的平均评级为 “持有”，共识目标价为 122.33 美元。</p>
<ul>
<li>3 只大型制药股投资超过 1000 亿美元在美国</li>
</ul>
<p><strong>查看我们关于 NVS 的最新报告</strong></p>
<h2>诺华股价上涨 0.6%</h2>
<p>NVS 股票在周二开盘价为 127.07 美元。该公司的速动比率为 0.62，流动比率为 0.88，债务与股本比率为 0.50。诺华制药的 12 个月最低价为 96.06 美元，12 个月最高价为 133.55 美元。该公司的市值为 2684.3 亿美元，市盈率为 17.36，PEG 比率为 1.93，贝塔值为 0.60。该公司的 50 日移动平均线为 127.31 美元，200 日移动平均线为 120.91 美元。</p>
<ul>
<li>3 只可能在市场波动后飙升的动量股</li>
</ul>
<p>诺华（NYSE:NVS - 获取免费报告）在 10 月 28 日最后一次公布季度财报。该公司报告本季度每股收益为 2.25 美元，低于分析师一致预期的 2.26 美元（差 0.01 美元）。诺华的股本回报率为 41.21%，净利润率为 26.49%。该公司本季度的收入为 139.1 亿美元，而分析师预期为 137 亿美元。去年同期，该公司的每股收益为 2.06 美元。诺华本季度的收入较去年同期增长了 8.5%。作为一个整体，股票研究分析师预计诺华制药在当前年度将发布 8.45 美元的每股收益。</p>
<h2>诺华公司简介</h2>
<p>（免费报告）</p>
<p>诺华制药公司在瑞士及国际上从事医疗产品的研究、开发、生产和营销。该公司为患者和医生提供处方药。它专注于心血管、肾脏和代谢、免疫学、神经科学和肿瘤学等治疗领域，以及眼科和血液学。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票而非诺华</li>
<li>投资于高市盈率成长股</li>
<li>内部人士在这三只股票上大举抛售——你应该担心吗？</li>
<li>10 月值得考虑购买的三只股票</li>
<li>股价下跌，目标价上调：三只在上涨 10% 后被升级的股票</li>
<li>投资中的降级意味着什么？</li>
<li>核能股票正在崩溃——投资者应该恐慌吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在诺华吗？</h2>
<p>在你考虑诺华之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而诺华并不在名单上。</p>
<p>虽然诺华目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

诺华制药

<p>金卢瑟资本管理公司在第二季度将其在诺华制药的持股增加了 27.4%，额外购买了 3,038 股，总持股达到 14,106 股，价值 170 万美元。其他机构投资者也调整了他们的持仓。分析师对诺华的评级褒贬不一，平均评级为 “持有”，目标价为 122.33 美元。诺华报告第三季度每股收益为 2.25 美元，略低于预期，但收入同比增长 8.5%，达到 139.1 亿美元</p>

<p>King Luther Capital Management Corp boosted its stake in shares of Novartis AG (NYSE:NVS - Free Report) by 27.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,106 shares of the company's stock after acquiring an additional 3,038 shares during the quarter. King Luther Capital Management Corp's holdings in Novartis were worth $1,707,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>金卢瑟资本管理公司在最近向证券交易委员会（SEC）提交的 13F 表格中披露，在第二季度将其在诺华制药（NYSE:NVS - 免费报告）股票中的持股比例提高了 27.4%。该机构投资者在本季度额外购买了 3,038 股后，持有该公司 14,106 股股票。根据其最近的 SEC 文件，金卢瑟资本管理公司在诺华的持股价值为 1,707,000 美元。</p>
</div><ul>
<li>Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver</li>
</ul>
<div class="lb-trans"><ul>
<li>诺华的月球计划癌症疗法可能成为未来的增长驱动力</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently made changes to their positions in the company. Midwest Trust Co acquired a new stake in shares of Novartis during the 2nd quarter worth about $32,297,000. Parkside Financial Bank &amp; Trust grew its stake in Novartis by 3.7% during the second quarter. Parkside Financial Bank &amp; Trust now owns 4,623 shares of the company's stock worth $559,000 after buying an additional 166 shares during the last quarter. Prospera Financial Services Inc increased its holdings in shares of Novartis by 21.0% during the second quarter. Prospera Financial Services Inc now owns 26,483 shares of the company's stock worth $3,206,000 after buying an additional 4,598 shares in the last quarter. AE Wealth Management LLC increased its holdings in shares of Novartis by 8.6% during the second quarter. AE Wealth Management LLC now owns 7,289 shares of the company's stock worth $882,000 after buying an additional 580 shares in the last quarter. Finally, Legacy Investment Solutions LLC bought a new position in shares of Novartis in the second quarter valued at approximately $30,000. Institutional investors and hedge funds own 13.12% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也对该公司的持股进行了调整。中西部信托公司在第二季度新购入了价值约 32,297,000 美元的诺华股票。Parkside 金融银行和信托在第二季度将其在诺华的持股增加了 3.7%。Parkside 金融银行和信托目前持有 4,623 股该公司的股票，价值 559,000 美元，此前在上个季度又购买了 166 股。Prospera 金融服务公司在第二季度将其在诺华的持股增加了 21.0%。Prospera 金融服务公司目前持有 26,483 股该公司的股票，价值 3,206,000 美元，此前在上个季度又购买了 4,598 股。AE 财富管理公司在第二季度将其在诺华的持股增加了 8.6%。AE 财富管理公司目前持有 7,289 股该公司的股票，价值 882,000 美元，此前在上个季度又购买了 580 股。最后，Legacy 投资解决方案公司在第二季度新购入了价值约 30,000 美元的诺华股票。机构投资者和对冲基金持有该公司 13.12% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>NVS has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a &#34;buy (b-)&#34; rating on shares of Novartis in a report on Friday, October 31st. Cfra Research upgraded Novartis to a &#34;hold&#34; rating in a report on Wednesday, October 29th. Deutsche Bank Aktiengesellschaft reaffirmed a &#34;buy&#34; rating on shares of Novartis in a report on Thursday, August 21st. Morgan Stanley upgraded shares of Novartis from an &#34;equal weight&#34; rating to an &#34;overweight&#34; rating in a research report on Friday, October 31st. Finally, Jefferies Financial Group restated a &#34;hold&#34; rating on shares of Novartis in a research report on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, Novartis currently has an average rating of &#34;Hold&#34; and a consensus target price of $122.33.</p>
<div class="lb-trans"><p>NVS 最近成为多份分析师报告的主题。Weiss 评级在 10 月 31 日的报告中重申了对诺华股票的 “买入（b-）” 评级。Cfra 研究在 10 月 29 日的报告中将诺华的评级上调至 “持有”。德意志银行在 8 月 21 日的报告中重申了对诺华股票的 “买入” 评级。摩根士丹利在 10 月 31 日的研究报告中将诺华股票的评级从 “持平” 上调至 “超配”。最后，杰富瑞金融集团在 10 月 27 日的研究报告中重申了对诺华股票的 “持有” 评级。一位投资分析师对该股票给予了强烈买入评级，三位给予了买入评级，七位给予了持有评级，三位给予了卖出评级。根据 MarketBeat.com 的数据，诺华目前的平均评级为 “持有”，共识目标价为 122.33 美元。</p>
</div><ul>
<li>3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只大型制药股投资超过 1000 亿美元在美国</li>
</ul>
</div><p><strong>View Our Latest Report on NVS</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 NVS 的最新报告</strong></p>
</div><h2>Novartis Trading Up 0.6%</h2>
<div class="lb-trans"><h2>诺华股价上涨 0.6%</h2>
</div><p>NVS stock opened at $127.07 on Tuesday. The company has a quick ratio of 0.62, a current ratio of 0.88 and a debt-to-equity ratio of 0.50. Novartis AG has a twelve month low of $96.06 and a twelve month high of $133.55. The company has a market cap of $268.43 billion, a P/E ratio of 17.36, a PEG ratio of 1.93 and a beta of 0.60. The business has a fifty day moving average of $127.31 and a 200-day moving average of $120.91.</p>
<div class="lb-trans"><p>NVS 股票在周二开盘价为 127.07 美元。该公司的速动比率为 0.62，流动比率为 0.88，债务与股本比率为 0.50。诺华制药的 12 个月最低价为 96.06 美元，12 个月最高价为 133.55 美元。该公司的市值为 2684.3 亿美元，市盈率为 17.36，PEG 比率为 1.93，贝塔值为 0.60。该公司的 50 日移动平均线为 127.31 美元，200 日移动平均线为 120.91 美元。</p>
</div><ul>
<li>3 Momentum Stocks That Could Soar Post-Market Volatility</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只可能在市场波动后飙升的动量股</li>
</ul>
</div><p>Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $2.25 EPS for the quarter, missing analysts' consensus estimates of $2.26 by ($0.01). Novartis had a return on equity of 41.21% and a net margin of 26.49%.The firm had revenue of $13.91 billion during the quarter, compared to analyst estimates of $13.70 billion. During the same quarter in the previous year, the business earned $2.06 earnings per share. Novartis's revenue for the quarter was up 8.5% compared to the same quarter last year. As a group, equities research analysts expect that Novartis AG will post 8.45 EPS for the current year.</p>
<div class="lb-trans"><p>诺华（NYSE:NVS - 获取免费报告）在 10 月 28 日最后一次公布季度财报。该公司报告本季度每股收益为 2.25 美元，低于分析师一致预期的 2.26 美元（差 0.01 美元）。诺华的股本回报率为 41.21%，净利润率为 26.49%。该公司本季度的收入为 139.1 亿美元，而分析师预期为 137 亿美元。去年同期，该公司的每股收益为 2.06 美元。诺华本季度的收入较去年同期增长了 8.5%。作为一个整体，股票研究分析师预计诺华制药在当前年度将发布 8.45 美元的每股收益。</p>
</div><h2>Novartis Company Profile</h2>
<div class="lb-trans"><h2>诺华公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.</p>
<div class="lb-trans"><p>诺华制药公司在瑞士及国际上从事医疗产品的研究、开发、生产和营销。该公司为患者和医生提供处方药。它专注于心血管、肾脏和代谢、免疫学、神经科学和肿瘤学等治疗领域，以及眼科和血液学。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Novartis</li>
<li>Investing in the High PE Growth Stocks</li>
<li>Insiders Sold Big at These 3 Stocks—Should You Worry?</li>
<li>3 Stocks to Consider Buying in October</li>
<li>Shares Down, Price Targets Up: 3 Stocks Upgraded After +10% Drops</li>
<li>What Does Downgrade Mean in Investing?</li>
<li>Nuclear Stocks Are Melting Down—Should Investors Panic?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票而非诺华</li>
<li>投资于高市盈率成长股</li>
<li>内部人士在这三只股票上大举抛售——你应该担心吗？</li>
<li>10 月值得考虑购买的三只股票</li>
<li>股价下跌，目标价上调：三只在上涨 10% 后被升级的股票</li>
<li>投资中的降级意味着什么？</li>
<li>核能股票正在崩溃——投资者应该恐慌吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=NVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Novartis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在诺华吗？</h2>
</div><p>Before you consider Novartis, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑诺华之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而诺华并不在名单上。</p>
</div><p>While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然诺华目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

King Luther Capital Management Corp 购买了 3,038 股诺华制药（Novartis AG）的股票，代码为$NVS